Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation

Area of Science:

• Oncology
• Molecular Biology
• Cancer Cell Biology

Background:

• X-linked inhibitor of apoptosis (XIAP) promotes cancer cell survival and chemoresistance.
• Prostate cancer (PCa) cells, particularly hormone-refractory PCa (HRPC), exhibit resistance to conventional therapies.
• Understanding XIAP's role is crucial for developing effective PCa treatments.

Purpose of the Study:

• To investigate the effects of transient and chronic downregulation of XIAP in HRPC cells.
• To determine the impact of XIAP modulation on apoptosis, Bcl-2 levels, and chemosensitivity.
• To explore adaptive mechanisms of PCa cells to XIAP loss.

Main Methods:

• Utilized DU145 HRPC cell line.
• Employed siRNA for transient XIAP downregulation (24 hours).
• Used shRNA vector stable transfection for chronic XIAP downregulation (beyond 1 month).
• Assessed apoptosis levels, Bcl-2 protein expression, and sensitivity to cisplatin.

Main Results:

• Transient XIAP downregulation increased apoptosis and decreased Bcl-2 levels.
• Transient XIAP knockdown sensitized PCa cells to cisplatin chemotherapy.
• Chronic XIAP downregulation via stable transfection resulted in Bcl-2 protein upregulation.
• PCa cells demonstrated adaptability to sustained XIAP loss through Bcl-2 upregulation.

Conclusions:

• Prostate cancer cells can adapt to chronic XIAP loss by upregulating Bcl-2.
• Transient XIAP inhibition enhances apoptosis and chemosensitivity.
• Multitargeting strategies are recommended for effective chemotherapy in human HRPC.